Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Levitee Labs Announces Philip Van Den Berg to Join as Interim CEO and the Board of Directors and Close First Tranche of Private Placement for $1.5 Million

Levitee Labs Announces Philip Van Den Berg to Join as Interim CEO and the Board of Directors and Close First Tranche of Private Placement for $1.5 Million

  • Post published:February 1, 2022
  • Post category:Press Release
Read more about the article Levitee Labs Announces Medical Advisory Board

Levitee Labs Announces Medical Advisory Board

  • Post published:January 6, 2022
  • Post category:Press Release
Read more about the article Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada

Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada

  • Post published:October 14, 2021
  • Post category:Press Release
Read more about the article Levitee Labs Announces DTC Eligibility Approval

Levitee Labs Announces DTC Eligibility Approval

  • Post published:September 24, 2021
  • Post category:Press Release
Read more about the article Levitee Labs Commences Trading in U.S. Under Ticker LVTTF

Levitee Labs Commences Trading in U.S. Under Ticker LVTTF

  • Post published:September 9, 2021
  • Post category:Press Release
Read more about the article Levitee Labs Appoints NIH Physician-Scientist Dr. Fady Hannah-Shmouni as Chief Medical and Scientific Officer

Levitee Labs Appoints NIH Physician-Scientist Dr. Fady Hannah-Shmouni as Chief Medical and Scientific Officer

  • Post published:August 5, 2021
  • Post category:Press Release
Read more about the article Levitee Labs Acquires Five Addiction Clinics in Alberta

Levitee Labs Acquires Five Addiction Clinics in Alberta

  • Post published:July 29, 2021
  • Post category:Press Release
Read more about the article Levitee Labs Acquires Three Specialized Alberta Pharmacies

Levitee Labs Acquires Three Specialized Alberta Pharmacies

  • Post published:July 29, 2021
  • Post category:Press Release
Read more about the article Levitee Labs Announces Completion of Acquisition of BlockMD Telemedicine Platform

Levitee Labs Announces Completion of Acquisition of BlockMD Telemedicine Platform

  • Post published:July 28, 2021
  • Post category:Press Release
Read more about the article Levitee Labs Signs Definitive Agreements to Acquire Clinics, Pharmacies, and a Telemedicine Company in Alberta

Levitee Labs Signs Definitive Agreements to Acquire Clinics, Pharmacies, and a Telemedicine Company in Alberta

  • Post published:July 23, 2021
  • Post category:Press Release

End of content

No more pages to load

Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More